Contact
FUNCTIONAL PRECISION ONCOLOGY

The right drug.
The first time.
Every time.

In cancer care, time is of the essence—patients need a prompt, accurate diagnosis and a clear path to the most appropriate treatment without unnecessary delay. SOLVDDX is developing a patient-specific oncology platform designed to begin at diagnosis—preserving viable tissue with non-formalin reagents.

Explore the PlatformInvestor Overview
WHY SOLVDDX

Diagnosis should start
the treatment conversation.

Traditional tissue handling can close the door on functional testing before treatment decisions even begin. SOLVDDX is designed around non-formalin specimen collection that protects tissue architecture while preserving viable cells for live-tumor analysis. Pathology confirms the disease before functional testing; its findings are then integrated with functional drug response, next-generation sequencing, pharmacogenomics and clinical evidence to help physicians evaluate how the tumor may respond and how the patient may process therapy.

TODAY

What should work?

Treatment is selected using population evidence, biomarkers, guidelines and prior experience.

  • Guidelines
  • Biomarkers
  • Genomics
  • Historical response
  • Physician judgment
SOLVDDX

What does this patient's tumor actually do?

Functional testing adds patient-specific response information and integrates it with molecular and clinical evidence.

  • Living tumor response
  • Molecular context
  • Clinical context
  • Ranked options
THE PLATFORM

From live tumor sample to explainable treatment ranking.

Fresh tissue is collected in specialized non-formalin media from one coordinated specimen pathway. Confirmed pathology diagnosis establishes the foundation for subsequent functional testing and informed therapy-management decisions. SOLVDDX is being built as a clinical decision platform—not simply a chemosensitivity assay.

FIG. 02FUNCTIONAL WORKFLOW
  1. 1 / SPECIMEN

    Collect viable tissue in non-formalin media

  2. 2 / DIAGNOSIS

    Confirm pathology diagnosis

  3. 3 / ASSAY

    Test drugs and clinical regimens

  4. 4 / RESPONSE

    Measure functional response

  5. 5 / INTEGRATE

    Integrate pathology, NGS, PGx and exposure

  6. 6 / RANK

    Rank options with rationale and confidence

Treatment Suitability Score

Designed to rank clinically relevant options using live tumor response, regimen testing, drug exposure, molecular concordance and clinical evidence.

Evidence Confidence Score

Designed to separately communicate the reliability and strength of the evidence supporting each recommendation.

Suitability
= relative treatment suitability based on integrated evidence
Confidence
= strength and completeness of supporting evidence
FIG. 03TREATMENT RANKING — CONCEPTUAL
CONCEPTUAL REGIMEN COMPARISONS / C
1Regimen A
Treatment Suitability87
Evidence Confidence74
2Regimen B
Treatment Suitability69
Evidence Confidence65
3Regimen C
Treatment Suitability52
Evidence Confidence59

Conceptual interface — illustrative only. Not clinical results.

INITIAL CLINICAL FOCUS

Starting where losing time
can matter most.

SOLVDDX's initial development focus is pancreatic ductal adenocarcinoma (PDAC), with prospective clinical validation and expansion contemplated across additional solid tumors.

PDACPancreatic Ductal AdenocarcinomaInitial cancer indication
INITIAL INDICATIONINDICATION / 1
DEVELOPMENT FOCUSSOLID TUMOR
100Patient validation objective
Multi-modalFunctional + molecular + clinical evidence
Regimen-levelBuilt around real treatment decisions
TECHNOLOGY & IP

A platform built around integration.

FUNCTIONAL ONCOLOGY

Live tumor response

Evaluate patient-specific response to selected agents and clinically relevant combinations.

INTEGRATED EVIDENCE

Pathology + NGS + PGx

Reconcile multiple evidence types rather than relying on a single biomarker or assay.

DECISION INTELLIGENCE

Explainable regimen ranking

Separate treatment suitability from confidence and generate a traceable physician-facing rationale.

FIG. 04 EVIDENCE INTEGRATION
LIVE RESPONSEPATHOLOGYNGSPGxDRUG EXPOSUREEVIDENCEINTEGRATIONTREATMENT RANKINGRATIONALE / CONFIDENCETRACEABLE PHYSICIAN-FACING OUTPUTLIVE RESPONSEPATHOLOGYNGSPGxDRUG EXPOSUREEVIDENCE INTEGRATIONTREATMENT RANKINGRATIONALE / CONFIDENCETRACEABLE PHYSICIAN-FACING OUTPUT
INVESTOR OPPORTUNITY

Build the clinical test—
and the data platform behind it.

Each completed case can contribute to a proprietary longitudinal dataset linking tumor biology, molecular profile, functional response, treatment choice and clinical outcome.

FIG. 05LONGITUDINAL DATA ARCHITECTURE
  1. Tumor biology
  2. Molecular profile
  3. Functional response
  4. Treatment choice
  5. Clinical outcome
  6. Longitudinal dataset
  • CASE 1INDEXED
  • CASE 2INDEXED
  • CASE 3INDEXED
  • …CONTINUOUS
  • LONGITUDINAL DATAGROWING ASSET
1

Clinical testing

SERVICE LAYER

Patient-specific functional oncology services.

2

Pharma partnerships

R&D LAYER

Drug development, biomarker work and combination screening.

3

Clinical trials

TRIAL LAYER

Potential patient-selection and response-prediction applications.

4

Data & AI

DATA LAYER

Longitudinal response/outcome datasets and predictive-model development.

CURRENT FINANCING

$6M

at a $65M pre-money valuation

Illustrative post-money valuation:$71M
Investor ownership at a full $6M closing:approximately 8.45%,before other financing-related dilution.
Capital priorities:
  • 1 / VALIDATIONPDAC validation
  • 2 / LABlab infrastructure
  • 3 / SYSTEMSAI/LIMS and report engine
  • 4 / TEAMpersonnel
  • 5 / MARKETcommercialization
  • 6 / ACCESSregulatory/reimbursement
  • 7 / ASSETSIP
  • 8 / OPERATIONSworking capital
SOLVDDX

The right drug.
The first time.
Every time.

Because patients may not get unlimited chances to find the therapy that works. SOLVDDX is developing a functional precision oncology platform intended to complement—not replace—oncologists, clinical guidelines, molecular profiling and clinical judgment.

General Inquiriesinfo@solvddx.com
Headquarters7791 N.W. 46 Street, Suite 218
Doral, Florida 33166, US
Contact+1 (855) 96-DEVON

Currently routed through Devon International Group.